Literature DB >> 18523011

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.

Douglas C Palmer1, Chi-Chao Chan, Luca Gattinoni, Claudia Wrzesinski, Chrystal M Paulos, Christian S Hinrichs, Daniel J Powell, Christopher A Klebanoff, Steven E Finkelstein, Robert N Fariss, Zhiya Yu, Robert B Nussenblatt, Steven A Rosenberg, Nicholas P Restifo.   

Abstract

Nonmutated tissue differentiation antigens expressed by tumors are attractive targets for cancer immunotherapy, but the consequences of a highly effective antitumor immune response on self-tissue have not been fully characterized. We found that the infusion of ex vivo expanded adoptively transferred melanoma/melanocyte-specific CD8+ T cells that mediated robust tumor killing also induced autoimmune destruction of melanocytes in the eye. This severe autoimmunity was associated with the up-regulation of MHC class I molecules in the eye and high levels of IFN-gamma derived from both adoptively transferred CD8+ T cells and host cells. Furthermore, ocular autoimmunity required the presence of the IFN-gamma receptor on target tissues. Data compiled from >200 eyes and tumors in 10 independently performed experiments revealed a highly significant correlation (P < 0.0001) between the efficacy of tumor immunotherapy and the severity of ocular autoimmunity. Administration of high doses of steroids locally mitigated ocular autoimmunity without impairing the antitumor effect. These findings have particular importance for immunotherapies directed against self-antigens and highlight the need for targeting unique tumor antigens not expressed in critical tissues.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18523011      PMCID: PMC2409137          DOI: 10.1073/pnas.0710929105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

Review 2.  Immunotherapy for gynaecological malignancies.

Authors:  George Coukos; Jose R Conejo-Garcia; Richard B S Roden; T-C Wu
Journal:  Expert Opin Biol Ther       Date:  2005-09       Impact factor: 4.388

Review 3.  Adoptive immunotherapy for cancer: building on success.

Authors:  Luca Gattinoni; Daniel J Powell; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

4.  Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin.

Authors:  Anna Charalambous; Margarita Oks; Godwin Nchinda; Sayuri Yamazaki; Ralph M Steinman
Journal:  J Immunol       Date:  2006-12-15       Impact factor: 5.422

5.  Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.

Authors:  Steven A Rosenberg; Richard M Sherry; Kathleen E Morton; William J Scharfman; James C Yang; Suzanne L Topalian; Richard E Royal; Udai Kammula; Nicholas P Restifo; Marybeth S Hughes; Douglas Schwartzentruber; David M Berman; Susan L Schwarz; Lien T Ngo; Sharon A Mavroukakis; Donald E White; Seth M Steinberg
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

6.  Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.

Authors:  Chrystal M Paulos; Claudia Wrzesinski; Andrew Kaiser; Christian S Hinrichs; Marcello Chieppa; Lydie Cassard; Douglas C Palmer; Andrea Boni; Pawel Muranski; Zhiya Yu; Luca Gattinoni; Paul A Antony; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

Review 7.  Identification of T-cell epitopes for cancer immunotherapy.

Authors:  J H Kessler; C J M Melief
Journal:  Leukemia       Date:  2007-07-05       Impact factor: 11.528

Review 8.  Human T cell responses against melanoma.

Authors:  Thierry Boon; Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

9.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors:  Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307

Review 10.  Integrating epitope data into the emerging web of biomedical knowledge resources.

Authors:  Bjoern Peters; Alessandro Sette
Journal:  Nat Rev Immunol       Date:  2007-06       Impact factor: 53.106

View more
  58 in total

Review 1.  Therapeutic cancer vaccines: are we there yet?

Authors:  Christopher A Klebanoff; Nicolas Acquavella; Zhiya Yu; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.

Authors:  Ami A Shah; Antony Rosen; Laura Hummers; Fredrick Wigley; Livia Casciola-Rosen
Journal:  Arthritis Rheum       Date:  2010-09

3.  Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma.

Authors:  Bradley J Seaman; Elizabeth A Guardiani; Carmen C Brewer; Christopher K Zalewski; Kelly A King; Susan Rudy; Carter Van Waes; Richard A Morgan; Mark E Dudley; James C Yang; Steven A Rosenberg; H Jeffrey Kim
Journal:  Otolaryngol Head Neck Surg       Date:  2012-05-17       Impact factor: 3.497

4.  SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.

Authors:  Jungsun Park; Amjad H Talukder; Seon A Lim; Kwanghee Kim; Ke Pan; Brenda Melendez; Sherille D Bradley; Kyle R Jackson; Jahan S Khalili; Junmei Wang; Caitlin Creasy; Bih-Fang Pan; Scott E Woodman; Chantale Bernatchez; David Hawke; Patrick Hwu; Kyung-Mi Lee; Jason Roszik; Gregory Lizée; Cassian Yee
Journal:  Cancer Immunol Res       Date:  2017-06-19       Impact factor: 11.151

5.  Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

Authors:  Christian S Hinrichs; Zachary A Borman; Luca Gattinoni; Zhiya Yu; William R Burns; Jianping Huang; Christopher A Klebanoff; Laura A Johnson; Sid P Kerkar; Shicheng Yang; Pawel Muranski; Douglas C Palmer; Christopher D Scott; Richard A Morgan; Paul F Robbins; Steven A Rosenberg; Nicholas P Restifo
Journal:  Blood       Date:  2010-10-22       Impact factor: 22.113

6.  Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

Authors:  Christian S Hinrichs; Zachary A Borman; Lydie Cassard; Luca Gattinoni; Rosanne Spolski; Zhiya Yu; Luis Sanchez-Perez; Pawel Muranski; Steven J Kern; Carol Logun; Douglas C Palmer; Yun Ji; Robert N Reger; Warren J Leonard; Robert L Danner; Steven A Rosenberg; Nicholas P Restifo
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-24       Impact factor: 11.205

7.  Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.

Authors:  Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Douglas C Palmer; Luca Gattinoni; Nicholas P Restifo
Journal:  Blood       Date:  2009-06-26       Impact factor: 22.113

Review 8.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  Ikaros imposes a barrier to CD8+ T cell differentiation by restricting autocrine IL-2 production.

Authors:  Shaun O'Brien; Rajan M Thomas; Gerald B Wertheim; Fuqin Zhang; Hao Shen; Andrew D Wells
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

10.  Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.

Authors:  Claudia Wrzesinski; Chrystal M Paulos; Andrew Kaiser; Pawel Muranski; Douglas C Palmer; Luca Gattinoni; Zhiya Yu; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.